News articles about Cogentix Medical (NASDAQ:CGNT) have trended somewhat negative on Monday, according to Accern. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cogentix Medical earned a news sentiment score of -0.23 on Accern’s scale. Accern also gave news coverage about the medical device company an impact score of 46.5625482953516 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of Cogentix Medical (NASDAQ:CGNT) traded down $0.04 during mid-day trading on Monday, reaching $2.94. 48,800 shares of the company’s stock traded hands, compared to its average volume of 51,044. The stock has a market cap of $179.06, a PE ratio of -7.17 and a beta of 0.66. Cogentix Medical has a 1-year low of $1.55 and a 1-year high of $3.34.
A number of research firms have commented on CGNT. TheStreet raised shares of Cogentix Medical from a “d+” rating to a “c” rating in a research report on Thursday, November 9th. Aegis initiated coverage on shares of Cogentix Medical in a research report on Friday, December 1st. They issued a “buy” rating and a $4.75 target price for the company. Zacks Investment Research downgraded shares of Cogentix Medical from a “buy” rating to a “hold” rating in a research report on Wednesday, December 20th. Roth Capital initiated coverage on shares of Cogentix Medical in a research report on Wednesday, November 8th. They set a “buy” rating and a $4.00 price objective for the company. Finally, JMP Securities initiated coverage on shares of Cogentix Medical in a research report on Friday, October 6th. They set an “outperform” rating and a $5.00 price objective for the company. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $4.06.
Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).
Receive News & Ratings for Cogentix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical and related companies with MarketBeat.com's FREE daily email newsletter.